Clinical Trials · NCT00130845

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

CompletedPhase 3Octreotide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Novartis
Enrollment
312
Start date
Feb 2000
Locations
1 site, United States
Primary endpoint
time to progression of diabetic retinopathy
View Octreotide compound reference